Open AccessMolecular investigation of Pseudomonas aeruginosa mexAB-oprM efflux pump genes from clinical samples and their correlation with antibiotic resistance
Author(s) -
Afrah Jawad Abd AL-Zwaid,
Hussein Oleiwi Muttaleb Al-Dahmoshimoshi
Publication year - 2022
Publication title -
journal of applied and natural science
Language(s) - English
Resource type - Journals
eISSN - 2231-5209
pISSN - 0974-9411
DOI - 10.31018/jans.v14i1.3240
Subject(s) - pseudomonas aeruginosa , cefepime , microbiology and biotechnology , ceftazidime , meropenem , efflux , piperacillin , tobramycin , antibiotics , ticarcillin , imipenem , biology , antibiotic resistance , gentamicin , bacteria , genetics
Pseudomonas aeruginosa, one of the majority of common opportunistic infections, has become a public health concern, exhibiting intrinsic and acquired resistance to a wide range of antimicrobials. The present work aimed to study the correlation between the P. aeruginosa efflux pump mexAB-oprM genes and antibiotic resistance to different types of antibiotics. All 79 isolates were screened by Pseudomonas chromogenic agar, which was used as a selective medium for the isolation of P. aeruginosa. After incubation at 37°C for 24 hr, the results were confirmed by PCR using specific primer pairs for the 16S rDNA gene of Pseudomonas spp. and P. aeruginosa for identification of the isolates. MexABoprM genes were investigated by PCR. The antibiotic susceptibility test was accomplished according to CLSI-2021 using the disc diffusion method for 13 antibiotics. The results revealed that the antibiotic susceptibility of P. aeruginosa was highly resistant to ceftazidime (93.6%) and cefepime (77.2%). In comparison, high sensitivity for imipenem (77.2%) and meropenem (67%) was observed. The antibiotic resistance patterns revealed that 38% of isolates were MDR multidrug resistant and 41% were non-MDR, and the mexA(65\79), mexB(49\79) and oprM (37\79) genes were distributed as mexA 83.5%, mexB 63.29% and oprM 48.1%, respectively. The present study concluded that mexABoprM may be highly associated with resistance to ceftazidime and cefepime and moderately associated with piperacillin, gentamicin and tobramycin.